Lightlake Therapeutics Inc. , a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed a collaboration agreement with the Division of Pharmacotherapies and Medical Consequences of Drug Abuse of the National Institute on Drug Abuse , part of the National Institutes ... (more)
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130424005443&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130424005443&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment